871115-32-1

Basic information

• Product Name: TERT-BUTYL 4-AMINO-4-(AMINOMETHYL)PIPERIDINE-1-CARBOXYLATE
• Synonyms: 1-Boc-4-aMino-4-aMinoMethylpiperidine;1-N-Boc-4-amino-4-aminomethyl-piperidine;4-amino-4-aminomethyl-1-BOC-piperidine;tert-Butyl 4-amino-4-(aminomethyl);TERT-BUTYL 4-AMINO-4-(AMINOMETHYL)PIPERIDINE-1-CARBOXYLATE;1-Piperidinecarboxylic acid, 4-aMino-4-(aMinoMethyl)-, 1,1-diMethylethyl ester
• CAS NO: 871115-32-1
• Molecular Formula: C₁₁H₂₃N₃O₂
• Molecular Weight: 229.32
• Mol File: 871115-32-1.mol

Chemical Properties

• Boiling Point: 326.4±27.0 °C(Predicted)
• Appearance: /
• Density: 1.064±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.13±0.29(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-AMINO-4-(AMINOMETHYL)PIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-AMINO-4-(AMINOMETHYL)PIPERIDINE-1-CARBOXYLATE(871115-32-1)
• EPA Substance Registry System: TERT-BUTYL 4-AMINO-4-(AMINOMETHYL)PIPERIDINE-1-CARBOXYLATE(871115-32-1)

Safety Data

• Hazardous Substances Data: 871115-32-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 4-AMINO-4-(AMINOMETHYL)PIPERIDINE-1-CARBOXYLATE is used as a building block for the synthesis of various pharmaceuticals due to its enhanced stability and lipophilicity, which can improve the pharmacokinetic properties of the resulting drugs.
Used in Agrochemical Industry:
In the agrochemical industry, TERT-BUTYL 4-AMINO-4-(AMINOMETHYL)PIPERIDINE-1-CARBOXYLATE serves as a precursor for the development of new agrochemicals, leveraging its structural features to create compounds with potential pesticidal or herbicidal activities.
Used in Synthesis of Bioactive Compounds:
TERT-BUTYL 4-AMINO-4-(AMINOMETHYL)PIPERIDINE-1-CARBOXYLATE is used as a versatile precursor in the synthesis of bioactive compounds, taking advantage of its aminomethyl group to form diverse chemical entities with potential therapeutic or biological activity.
Used as a Ligand for Metal Catalysis:
In the field of catalysis, TERT-BUTYL 4-AMINO-4-(AMINOMETHYL)PIPERIDINE-1-CARBOXYLATE is utilized as a ligand for metal catalysts, contributing to the efficiency and selectivity of various chemical reactions, which can be beneficial in the synthesis of complex organic molecules.

Upstream product

• 331281-25-5 4-amino-4-cyano-piperidine-1-carboxylic acid tert-butyl ester 
• 871115-22-9 4-aminomethyl-4-(2,2,2-trifluoroacetylamino)piperidine-1-carboxylic acid tert-butyl ester 
• 871115-24-1 4-(2,2,2-trifluoroacetylamino)-4-[(2,2,2-trifluoroacetylamino)methyl]piperidine-1-carboxylic acid tert-butyl ester 
• 871115-20-7 4-cyano-4-(2,2,2-trifluoroacetylamino)piperidine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 1427596-50-6 4-amino-4-[(2,4-difluorobenzoylamino)methyl]piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Organic Compounds

A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins

A novel series of spirorifamycins was synthesized and their antibacterial activity evaluated both in vitro and in vivo. This new series of rifamycins shows excellent activity against Staphylococcus aureus that is equivalent to rifabutin. However, some compounds of the series exhibit lower MICs than rifabutin against rifampin-resistant strains of S. aureus. Further, compound 2e exhibits comparable efficacy in vivo in a murine model of S. aureus septicemia model following administration by either oral or parenteral dosing routes.

Spiro-rifamycin derivatives targeting RNA polymerase

Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to a series of novel spiro rifamycin derivatives which have demonstrated potent antimicrobial activity.